- Home
- IGA vs BDTX Comparison
IGA vs BDTX Comparison
Compare IGA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGA | BDTX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IGA | BDTX |
|---|---|---|
| Price | $9.72 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.60 |
| AVG Volume (30 Days) | 42.3K | ★ 919.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.77 | $1.20 |
| 52 Week High | $8.88 | $4.94 |
Technical Indicators
Market Signals| Indicator | IGA | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 43.76 |
| Support Level | $9.72 | $2.41 |
| Resistance Level | $9.84 | $2.78 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 27.78 | 70.30 |
Price Performance
Historical ComparisonAbout IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.